A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...
One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.
GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.
If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Inhalers will soon get a whole lot cheaper for some Americans. Three of the world's ...
* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD * TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY ...
If you have not heard already, one of the most popular inhalers has been discontinued by its manufacturer since January 1. GlaxoSmithKline (GSK) has stopped producing Flovent, which comes as a metered ...
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results